Last updated on April 2018

Open-Label Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Brief description of study

This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.

Detailed Study Description

Part 1A is a dose-escalation study in patients with any locally advanced or metastatic solid tumor or lymphoma for which standard therapies have been exhausted. Part 1B will further assess safety and evaluate PK of FPA144 in gastric cancer patients.

Part 2 patients will be enrolled and treated in order to further characterize safety and preliminary efficacy in a selected cancer patient population with the greatest potential for clinical benefit from FPA144 treatment.

Clinical Study Identifier: NCT02318329

Contact Investigators or Research Sites near you

Start Over

Eun Kee Song, MD

Chonbuk National University Hospital
Jeonju-si, Korea, Republic of

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.